Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

Completed · Phase 4 · Has a placebo group

Conditions studied: Pervasive Development Disorders

In brief

The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).

Key facts

Study ID

NCT01238575

Run by

Yale University

People needed

62

Starts

2011-12-01

Expected to finish

2014-03-01

Last updated by the study team

2020-03-31

Who can join

Age: 5 and older, up to 14. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of PDD (PDD-NOS, Asperger's Disorder, Autistic Disorder)
• Hyperactivity
• Between ages 5 years 0 months and 13 years 11 months.
• Weight >/= 15 kg (33 lb)
• A mental age of at least 18 months

You may not qualify if…

• Prior failed treatment with an adequate trial of guanfacine in the last 2 years
• Concurrent treatment with another psychoactive medication

Where it is running

• University of California, Los Angeles — Los Angeles, California, United States
• Yale University — New Haven, Connecticut, United States
• Emory University — Atlanta, Georgia, United States
• Massachusetts General Hospital — Lexington, Massachusetts, United States
• Seattle Children's Hospital — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.